Drugs Xagena
The FDA ( Food and Drug Administration ) has granted accelerated approval for an oral medication to treat patients with advanced non-small cell lung cancer ( NSCLC ). Tagrisso ( Osimertinib ) is now ...
The FDA ( Food and Drug Administration ) has approved a new second-generation lung cancer treatment that can help many patients in their battle against the disease. Lung cancer patients got another ro ...
The FDA ( Food and Drug Administration ) has granted full approval for Tagrisso ( Osimertinib ) 80mg once-daily tablets, for the treatment of patients with metastatic epidermal growth factor receptor ...
The European Commission has granted marketing authorisation for Tagrisso ( Osimertinib ), a third-generation, irreversible EGFR-TKI, as monotherapy for the 1st-line treatment of adult patients with lo ...
The Food and Drug Administration ( FDA ) has approved Osimertinib ( Tagrisso ) for the first-line treatment of patients with metastatic non-small cell lung cancer ( NSCLC ) whose tumors have epidermal ...
The FDA ( U.S. Food and Drug Administration ) has approved Tagrisso ( Osimertinib ) as the first adjuvant treatment for patients with non-small cell lung cancer whose tumors have a specific type of ge ...
Tagrisso ( Osimertinib ), an irreversible epidermal growth factor receptor tyrosine kinase inhibitor ( EGFR TKI ), has been approved in the European Union ( EU ) for the adjuvant treatment of adult pa ...
